Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Shinobu Shimizu, Masahiro Iijima, Yuki Fukami, Natsuko Tamura, Masahiro Nakatochi, Masahiko Ando, Ryoji Nishi, Haruki Koike, Kenichi Kaida, Michiaki Koga, Takashi Kanda, Hidenori Ogata, Jun-Ichi Kira, Masahiro Mori, Satoshi Kuwabara, Masahisa Katsuno, Shinobu Shimizu, Masahiro Iijima, Yuki Fukami, Natsuko Tamura, Masahiro Nakatochi, Masahiko Ando, Ryoji Nishi, Haruki Koike, Kenichi Kaida, Michiaki Koga, Takashi Kanda, Hidenori Ogata, Jun-Ichi Kira, Masahiro Mori, Satoshi Kuwabara, Masahisa Katsuno

Abstract

Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated peripheral neuropathy that is currently classified into several clinical subtypes, which are presumed to have different pathogenic mechanisms. Recently, studies identified a subgroup of patients with CIDP who were positive for IgG4 autoantibodies against paranodal proteins, such as neurofascin-155 and contactin-1, who respond poorly to first-line therapies for typical CIDP, including intravenous immunoglobulin therapy.

Objective: This study aims to evaluate the efficacy and safety of intravenous rituximab according to IgG4 autoantibody status in patients with refractory CIDP.

Methods: The Evaluation of the Efficacy and Safety of Rituximab in Refractory CIDP Patients with IgG4 Autoantibodies in the Exploratory Clinical (RECIPE) trial consists of 2 cohorts: a multicenter, placebo-controlled, randomized study cohort of 15 patients with IgG4 autoantibody-positive CIDP (rituximab:placebo = 2:1) and an open-label trial cohort of 10 patients with antibody-negative CIDP. The primary endpoint is improvement in functional outcome assessed using the adjusted Inflammatory Neuropathy Cause and Treatment Disability Scale score at 26, 38, or 52 weeks after the start of treatment with rituximab in patients with CIDP and anti-paranodal protein antibodies. Secondary outcome measures include grip strength, manual muscle testing sum scores, results of nerve conduction studies, and other functional scales.

Results: We plan to enroll 25 cases for the full analysis set. Recruitment is ongoing, with 14 patients enrolled as of January 2020. Enrollment will close in September 2020, and the study is planned to end in December 2021.

Conclusions: This randomized controlled trial will determine if rituximab is safe and effective in patients with anti-paranodal antibodies. An open-label study will provide additional data on the effects of rituximab in patients with antibody-negative CIDP. The results of the RECIPE trial are expected to provide evidence for the positioning of rituximab as a pathogenesis-based therapeutic for refractory CIDP.

Trial registration: ClinicalTrials.gov NCT03864185, https://ichgcp.net/clinical-trials-registry/NCT03864185 ; The Japan Registry of Clinical Trials jRCT2041180037, https://jrct.niph.go.jp/en-latest-detail/jRCT2041180037.

International registered report identifier (irrid): DERR1-10.2196/17117.

Keywords: chronic inflammatory demyelinating polyradiculoneuropathy; clinical study; immunoglobulin G4 autoantibodies; partially randomized controlled trial; rituximab.

Conflict of interest statement

Conflicts of Interest: None declared.

©Shinobu Shimizu, Masahiro Iijima, Yuki Fukami, Natsuko Tamura, Masahiro Nakatochi, Masahiko Ando, Ryoji Nishi, Haruki Koike, Kenichi Kaida, Michiaki Koga, Takashi Kanda, Hidenori Ogata, Jun-Ichi Kira, Masahiro Mori, Satoshi Kuwabara, Masahisa Katsuno. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 01.04.2020.

Figures

Figure 1
Figure 1
Measurement schedule. CNTN!: Contactin-1; CSF: cerebrospinal fluid; IgG4-Ab: immunoglobulin G4 antibodies; INCAT: Inflammatory Neuropathy Cause and Treatment; MRC: Medical Research Council; NF155: Neurofascin-155; R-ODS: Rasch-built Overall Disability Scale.

References

    1. Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision. J Peripher Nerv Syst. 2010 Mar;15(1):1–9. doi: 10.1111/j.1529-8027.2010.00245.x.
    1. Van den Bergh PYK, Hadden RDM, Bouche P, Cornblath DR, Hahn A, Illa I, Koski CL, Léger J, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN, European Federation of Neurological Societies. Peripheral Nerve Society European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010 Mar;17(3):356–63. doi: 10.1111/j.1468-1331.2009.02930.x.
    1. Joint Task Force of the EFNS and the PNS Erratum of European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J Peripher Nerv Syst. 2010;15:373. doi: 10.1111/j.1529-8027.2010.00291.x.
    1. Van den Bergh PYK, Hadden RDM, Bouche P, Cornblath DR, Hahn A, Illa I, Koski CL, Léger JM, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN, European Federation of Neurological Societies. Peripheral Nerve Society Corrigendum of European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision. Eur J Neurol. 2011 Apr;18(5):796. doi: 10.1111/j.1468-1331.2011.03403.x.
    1. Laughlin RS, Dyck PJ, Melton LJ, Leibson C, Ransom J, Dyck PJB. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009 Jul 07;73(1):39–45. doi: 10.1212/WNL.0b013e3181aaea47.
    1. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009 Apr;39(4):432–8. doi: 10.1002/mus.21206.
    1. Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry. 1999 May;66(5):677–80. doi: 10.1136/jnnp.66.5.677.
    1. Chiò A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, Mutani R, Calvo A, PARCIDP Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1349–53. doi: 10.1136/jnnp.2007.114868.
    1. Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol. 2001 Mar;8(2):157–65. doi: 10.1046/j.1468-1331.2001.00187.x.
    1. McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol. 1999 Dec;46(6):910–3.
    1. Meléndez-Vásquez C, Redford J, Choudhary PP, Gray IA, Maitland P, Gregson NA, Smith KJ, Hughes RA. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol. 1997 Mar;73(1-2):124–34. doi: 10.1016/s0165-5728(96)00189-0.
    1. Kuwahara M, Suzuki S, Takada K, Kusunoki S. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 2011 Oct 28;239(1-2):87–90. doi: 10.1016/j.jneuroim.2011.08.016.
    1. Querol L, Siles AM, Alba-Rovira R, Jáuregui A, Devaux J, Faivre-Sarrailh C, Araque J, Rojas-Garcia R, Diaz-Manera J, Cortés-Vicente E, Nogales-Gadea G, Navas-Madroñal M, Gallardo E, Illa I. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep. 2017 Oct 31;7(1):14411. doi: 10.1038/s41598-017-14853-4. doi: 10.1038/s41598-017-14853-4.
    1. Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, Sekiguchi K, Kokubun N, Ichikawa H, Wong AHY, Yuki N. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016 Mar 01;86(9):800–7. doi: 10.1212/WNL.0000000000002418.
    1. Miura Y, Devaux JJ, Fukami Y, Manso C, Belghazi M, Wong AHY, Yuki N, CNTN1-CIDP Study Group Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain. 2015 Jun;138(Pt 6):1484–91. doi: 10.1093/brain/awv054.
    1. Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, Matsuse D, Kuwahara M, Suzuki H, Kusunoki S, Fujimoto Y, Ikezoe K, Kishida H, Tanaka F, Matsushita T, Murai H, Kira J. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol. 2015 Oct;2(10):960–71. doi: 10.1002/acn3.248. doi: 10.1002/acn3.248.
    1. Kadoya M, Kaida K, Koike H, Takazaki H, Ogata H, Moriguchi K, Shimizu J, Nagata E, Takizawa S, Chiba A, Yamasaki R, Kira JI, Sobue G, Ikewaki K. IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. J Neuroimmunol. 2016 Dec 15;301:16–22. doi: 10.1016/j.jneuroim.2016.10.013.
    1. Querol L, Nogales-Gadea G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A, Sedano MJ, Gallardo E, Berciano J, Blesa R, Dalmau J, Illa I. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014 Mar 11;82(10):879–86. doi: 10.1212/WNL.0000000000000205.
    1. Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, Benedetti L, Briani C, Fazio R, Jann S, Matà S, Sabatelli M, Nobile-Orazio E, Italian Network for CIDP Register Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011 Dec;18(12):1417–21. doi: 10.1111/j.1468-1331.2011.03495.x.
    1. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology. 1999 May 12;52(8):1701–4. doi: 10.1212/wnl.52.8.1701.
    1. Knecht H, Baumberger M, Tobòn A, Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology. 2004 Aug 24;63(4):730–2. doi: 10.1212/01.wnl.0000134606.50529.c7.
    1. Gono T, Matsuda M, Shimojima Y, Ishii W, Yamamoto K, Morita H, Hashimoto T, Susuki K, Yuki N, Ikeda S. Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. J Clin Neurosci. 2006 Jul;13(6):683–7. doi: 10.1016/j.jocn.2005.09.008.
    1. Münch C, Anagnostou P, Meyer R, Haas J. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci. 2007 May 15;256(1-2):100–2. doi: 10.1016/j.jns.2007.02.027.
    1. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007 Jan;35(1):66–9. doi: 10.1002/mus.20664.
    1. Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, Luigetti M, Sabatelli M, Giannini F, Mancardi GL, Schenone A, Nobile-Orazio E, Cocito D. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):306–8. doi: 10.1136/jnnp.2009.188912.
    1. Sadnicka A, Reilly MM, Mummery C, Brandner S, Hirsch N, Lunn MPT. Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):230–2. doi: 10.1136/jnnp.2009.174888.
    1. D'Amico A, Catteruccia M, De Benedetti F, Vivarelli M, Colucci M, Cascioli S, Bertini E. Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol. 2012 May;16(3):301–3. doi: 10.1016/j.ejpn.2011.08.002.
    1. Ware TL, Kornberg AJ, Rodriguez-Casero MV, Ryan MM. Childhood chronic inflammatory demyelinating polyneuropathy: an overview of 10 cases in the modern era. J Child Neurol. 2014 Jan;29(1):43–8. doi: 10.1177/0883073812471719.
    1. Velardo D, Riva N, Del Carro U, Bianchi F, Comi G, Fazio R. Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. J Neurol. 2017 May;264(5):1011–4. doi: 10.1007/s00415-017-8462-7.
    1. Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, Sedano MJ, Seró-Ballesteros L, Carvajal A, Ortiz N, Gallardo E, Illa I. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015 Sep 3;2(5):e149. doi: 10.1212/NXI.0000000000000149.
    1. Delmont E, Manso C, Querol L, Cortese A, Berardinelli A, Lozza A, Belghazi M, Malissart P, Labauge P, Taieb G, Yuki N, Illa I, Attarian S, Devaux JJ. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain. 2017 Jul 01;140(7):1851–8. doi: 10.1093/brain/awx124.
    1. Painous C, López-Pérez M�, Illa I, Querol L. Head and voice tremor improving with immunotherapy in an anti-NF155 positive CIDP patient. Ann Clin Transl Neurol. 2018 May 7;5(4):499–501. doi: 10.1002/acn3.539. doi: 10.1002/acn3.539.
    1. Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF, Howard D, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, LaBoy SM, Fellman MA, Greene SM, Pasnoor M, Burns TM. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology. 2017 Sep 05;89(10):1069–77. doi: 10.1212/WNL.0000000000004341.
    1. Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R, Suárez-Calvet X, Muñoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juárez C, Verschuuren JJ, Illa I. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012 Jan 17;78(3):189–93. doi: 10.1212/WNL.0b013e3182407982.
    1. Koike H, Kadoya M, Kaida K, Ikeda S, Kawagashira Y, Iijima M, Kato D, Ogata H, Yamasaki R, Matsukawa N, Kira JI, Katsuno M, Sobue G. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):465–73. doi: 10.1136/jnnp-2016-314895.
    1. van Schaik IN, Bril V, van Geloven N, Hartung H, Lewis RA, Sobue G, Lawo J, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, PATH study group Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018 Jan;17(1):35–46. doi: 10.1016/S1474-4422(17)30378-2.
    1. Léger J, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Shebl A, Bauhofer A, Zenker O, Merkies ISJ, PRIMA study investigators Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study) J Peripher Nerv Syst. 2013 Jun;18(2):130–40. doi: 10.1111/jns5.12017. doi: 10.1111/jns5.12017.
    1. The World Medical Association 2013. Oct, [2020-02-09]. Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj